Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements related to the SmithKline Beecham Employee Benefit Trust ("the Trust") on February 9, 2007:
- Share Sales: 5,805 Ordinary shares were sold on behalf of participants in the SmithKline Beecham Annual Investment Plan at a price of GBP 14.51 per share.
- Share Transfers: 18,851 Ordinary shares were transferred from the Trust to participants in the same plan.
Management Commentary and Risks
The Trust is identified as a discretionary fund where all non-US employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that Director Mr. J S Heslop holds an interest in the shares held in the fund in the same capacity as other non-US employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b). No other risks, contingencies, or unusual items are discussed in this text.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the scale of these transactions relative to the fund's total holdings.
- Confirm the current share price of GlaxoSmithKline plc to evaluate the significance of the GBP 14.51 transaction price.
- Review the full terms of the SmithKline Beecham Annual Investment Plan to understand the mechanics of the share transfers and sales.